Savara Inc. (SVRA) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole program is MOLBREEVI (molgramostim inhalation solution), an investigational inhaled biologic in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The company has no product revenue to date and operates as a single segment.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | Balance Sheet (June 30, 2026) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(40.2) million | $(77.5) million | N/A |
| Operating Expenses | $41.0 million | $80.0 million | N/A |
| Cash & Equivalents | N/A | N/A | $41.8 million |
| Short-term Investments | N/A | N/A | $131.2 million |
| Total Liquidity | N/A | N/A | $173.0 million |
| Long-term Debt | N/A | N/A | $30.1 million |
| Accumulated Deficit | N/A | N/A | $(685.6) million |
| Cash Used in Operations (YTD) | N/A | $(62.8) million | N/A |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the three months ended June 30, 2026, increased by $9.8 million (32.3%) compared to the same period in 2025, driven primarily by higher operating expenses.
- Expense Growth:
- General & Administrative (G&A): Increased by $8.3 million (78.2%) quarter-over-quarter. This was primarily due to a $7.5 million increase in personnel costs, driven by stock-based compensation and headcount growth to build the commercial team.
- Research & Development (R&D): Increased by $1.2 million (5.8%) quarter-over-quarter, mainly due to higher personnel costs and stock-based compensation.
- Liquidity Position: Total cash and short-term investments decreased from $235.7 million at December 31, 2025, to $173.0 million at June 30, 2026, reflecting operational cash burn and investment maturities.
- Debt Facility: The company amended its Hercules Loan Agreement in January 2026, extending compliance dates for financial covenants and maintaining a facility of up to $105 million, with $30.1 million currently drawn.
Outlook, Risks, and Management Commentary
- Regulatory Status: The FDA granted Priority Review for the MOLBREEVI Biologics License Application (BLA). In April 2026, the FDA extended the review period, setting a new PDUFA target action date of November 22, 2026. The European Medicines Agency (EMA) and UK MHRA have also validated marketing authorization applications.
- Capital Needs: Management states that while current liquidity ($173 million) is sufficient for planned activities, the company may need to raise additional capital to fund development, regulatory approval, and commercialization. Future funding may come from equity offerings, debt, or the royalty purchase agreement.
- Royalty Agreement: In October 2025, Savara entered an agreement with RTW Investments, LP, to receive up to $75 million upon FDA approval (by March 31, 2027) in exchange for a tiered royalty on U.S. net sales.
- Risks: Key risks include the failure to obtain regulatory approval, delays in the approval process, inability to raise additional capital on favorable terms, and the uncertainty of commercial success post-approval.
Investor Verification Checklist
- Regulatory Timeline: Verify the status of the FDA review extension and the November 22, 2026, PDUFA date for MOLBREEVI.
- Cash Runway: Assess the burn rate (approx. $62.8 million for 6 months) against current liquidity ($173 million) to estimate the runway without additional financing.
- Debt Covenants: Review the amended Hercules Loan Agreement covenants, specifically the "Cash Requirement" and "Conditional Minimum Revenue Covenant" compliance dates extended to 2027.
- Commercial Readiness: Evaluate the significant increase in G&A expenses related to commercial team hiring and whether this aligns with the projected launch timeline.
- Royalty Agreement Terms: Confirm the conditions for the $75 million payment from RTW Investments and the associated royalty obligations.